Vir Biotechnology financials
$10.65+1.33%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY19 Jan 31 | FY18 Jan 31 | FY17 Jan 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $68.6M | $74.2M | $86.2M | $1.62B | $1.10B | $76.4M | $8.1M | $200.7M | $189.3M | $173.4M |
| Gross profit | $68.5M | $73.4M | $83.4M | $1.47B | $1.03B | $76.4M | $8.1M | $67.1M | $65.5M | $62.5M |
| Gross margin | 100.0% | 98.9% | 96.8% | 90.9% | 94.0% | 100.0% | 100.0% | 33.4% | 34.6% | 36.1% |
| Operating income | -$479.3M | -$587.2M | -$684.3M | $833.1M | $420.8M | -$297.0M | -$178.0M | $1.1M | $3.9M | $5.9M |
| Net income | -$438.0M | -$522.0M | -$615.1M | $515.8M | $528.6M | -$298.7M | -$174.7M | -$1.6M | -$3.2M | $22.8M |
| Net margin | −638.9% | −703.4% | −713.7% | 31.9% | 48.3% | −391.1% | −2159.0% | −0.8% | −1.7% | 13.1% |
| Diluted EPS | $-3.16 | $-3.83 | $-4.59 | $3.83 | $3.96 | $-2.51 | $-5.76 | $-0.10 | $-0.21 | $1.49 |
| EBITDA | -$467.8M | -$537.6M | -$651.3M | $839.9M | $426.6M | -$291.5M | -$173.5M | $7.7M | $10.4M | $12.3M |
| Operating cash flow | -$391.8M | -$446.4M | -$778.8M | $1.66B | -$139.4M | -$229.3M | -$138.0M | $2.4M | $1.7M | $5.9M |
| Free cash flow | -$396.6M | -$453.7M | -$800.4M | $1.60B | -$161.3M | -$235.9M | -$146.9M | -$3.0M | -$11.7M | $1.5M |
| Diluted shares | 138.5M | 136.2M | 134.1M | 134.8M | 133.4M | 119.2M | 30.3M | 15.4M | 15.2M | 15.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $232.2M | $222.9M | $241.6M | $848.6M | $347.8M | $436.6M |
| Short-term investments | $234.8M | $682.4M | $1.28B | $1.55B | $360.3M | $300.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.00B | $1.40B | $1.92B | $2.80B | $1.95B | $918.8M |
| Total liabilities | $237.5M | $248.4M | $328.8M | $724.1M | $522.4M | $201.9M |
| Shareholders' equity | $765.3M | $1.15B | $1.59B | $2.08B | $1.43B | $716.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology